Intercept Pharma (ICPT) Misses Q4 EPS by 11c, Revenues Miss

Intercept Pharma (NASDAQ: ICPT) reported Q4 EPS of ($1.58), $0.11 worse than the analyst estimate of ($1.47). Revenue for the quarter came in at $83.27 million versus the consensus estimate of $85.01 million.

“As we turn the page on 2020, I am proud of the Intercept team’s efforts to support patients with PBC and grow our Ocaliva foundational rare disease franchise during a global pandemic,” said Jerry Durso, President and Chief Executive Officer of Intercept. “We continued our regulatory dialogue with FDA and EMA and met with the FDA in Q1 regarding the NISS for liver disorder in a subset of PBC patients with cirrhosis. While interactions remain ongoing, the process will ultimately result in a change to our label regarding the use of Ocaliva to treat patients who reach the most advanced stages of PBC.”

“Regarding our NASH regulatory process, we are laser-focused on building alignment with FDA in advance of a potential NDA resubmission, with the goal of increasing the probability of a successful outcome for patients with advanced fibrosis due to NASH,” Durso continued. “We are also looking forward to topline results from our phase 3 REVERSE trial in patients with compensated cirrhosis due to NASH this year.”

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Optimum Communications gets NYSE non-compliance notice over stock price